Agent for preventing or alleviating psychological disorders

Phosphoethanolamine-based agents address the need for effective prevention and alleviation of psychological disorders by increasing anandamide levels and reducing neutrophil recruitment, offering a new approach beyond traditional treatments.

JP2024159649APending Publication Date: 2024-11-08HUMAN METABOLOME TECH +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024071296
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-28
Filing Date
2024-04-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There is a growing need for simple and effective means to prevent or alleviate psychological disorders such as depression and cognitive decline, which are exacerbated by chronic stress and affect a significant portion of the global population, with existing treatments often being insufficient for pre-symptomatic or mild cases.

Method used

A preventive or alleviating agent containing phosphoethanolamine or its salt is developed, which can be administered orally or via injection, and is formulated into food, drinks, or medicines to improve mental health.

Benefits of technology

Phosphoethanolamine effectively suppresses symptoms of depression and cognitive decline by increasing anandamide levels, reducing neutrophil recruitment, and alleviating psychological stress, providing a novel mechanism of action distinct from conventional treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159649000003
    Figure 2024159649000003
  • Figure 2024159649000004
    Figure 2024159649000004
  • Figure 2024159649000005
    Figure 2024159649000005
Patent Text Reader

Abstract

To provide a novel agent for preventing or alleviating psychological disorders that may cause chronic stress.SOLUTION: An agent for preventing or alleviating psychological disorders comprises phosphoethanolamine or a salt thereof as an active ingredient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an agent for preventing or alleviating psychological disorders. [Background technology]

[0002] Depression and depressive states as psychological disorders are a type of mood disorder, and it is said that there are more than 300 million people suffering from them worldwide. In addition, if we include those who are not diagnosed with such psychological disorders but have an abnormal psychological state, many more people suffer from depression or a psychological state that could lead to depression. The number of people taking long-term leave from work and the number of suicides due to such abnormal psychological states continue to increase, and there are concerns about the breakdown of economic backgrounds and social structures, and assistance and support are being provided from various quarters. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Patent No. 2022-58747 [Non-patent literature]

[0004] [Non-Patent Document 1] Psychiatry and Clinical Neurosciences 2018; 72: 349-361 [Non-Patent Document 2] Seishin Shinkeigaku Zasshi 2010;112:10:1003-1008 Summary of the Invention [Problem to be solved by the invention]

[0005] An object of the present invention is to provide a novel agent for preventing or alleviating psychological disorders. [Means for solving the problem]

[0006] Under such circumstances, the present inventors have conducted extensive research and found that phosphoethanolamine or a salt thereof is effective in preventing or alleviating psychological disorders. The present invention is based on this novel finding. Therefore, the present invention provides the following: Item 1. An agent for preventing or alleviating psychological disorders, which contains phosphoethanolamine or a salt thereof as an active ingredient.

[0007] Item 2. The preventive or alleviating agent according to Item 1, wherein the psychological disorder is a condition caused by psychological stress.

[0008] Item 3. The prophylactic or alleviating agent according to Item 1, wherein the psychological disorder is at least one selected from the group consisting of cognitive disorder, social activity disorder, and mental disorder.

[0009] Item 4. The preventive or alleviating agent according to Item 1, which is for oral intake or injection administration.

[0010] Item 5. The preventive or alleviating agent according to Item 1, which is a food, beverage, or pharmaceutical product. Effect of the Invention

[0011] According to the present invention, a novel agent for preventing or alleviating psychological disorders is provided.

[0012] In recent years, psychological anxiety and disorders (mental health problems) have been increasing due to various stresses caused by the spread of infectious diseases, an increase in natural disasters, diversification of living and working environments, and the complexity of human relationships, even if they do not lead to illnesses such as mental disorders. In addition, the number of people who suffer from a decline in quality of life and pain due to this is increasing year by year. If such mental health problems continue for a long period of time, they may develop abnormalities such as depression and cognitive decline, and it is necessary to properly care for mental health problems. If the level is pathological, a medical institution can be consulted and medication or counseling can be used, but for people who feel psychological disorders such as feeling unwell on a daily basis even if they do not reach the point of receiving treatment, it is important to secure simple and effective means. Therefore, in order to care for mental health problems on a daily basis, there is a demand and supply for food, beverages, or medicines that can be easily consumed and are effective in improving mental health problems.

[0013] It has been reported that ethanolamine phosphate (phosphoethanolamine, PEA) is reduced in the plasma of patients with depression compared to healthy subjects (Patent Document 1 and Non-Patent Document 1). The literature also describes that anandamide phosphate is decomposed to PEA and anandamide. Anandamide is one of the neurotransmitters in the brain and is known to be involved in emotions such as "pleasure" and "joy". Therefore, it is expected that an increase in the amount of anandamide in the body suppresses depressive symptoms, and a decrease in the amount of anandamide will worsen depressive symptoms. It was also expected that anandamide phosphate is reduced in the body of patients with major depression, and that anandamide is therefore less likely to be produced. Therefore, phosphoethanolamine itself does not act on psychological disorders such as major depression, but is a by-product of anandamide and has been considered as an indicator of the amount of anandamide or anandamide phosphate in the body.

[0014] It has been known that depression and dementia are closely related (Non-Patent Document 2). Cognition is the mental act or process of gaining knowledge and understanding through thoughts, experiences and sensations. Cognitive impairment (also called cognitive decline) can be caused by certain metabolic disorders (amyloids) or depression induced for various reasons, damage to the brain due to neurodegenerative conditions (e.g., those in Alzheimer's disease), damage to the brain due to injuries, infections, substance abuse, substance withdrawal, mental illness, vitamin and other important nutrient deficiencies, hormonal problems, metabolic imbalances or side effects of drugs. Cognitive impairment also occurs as a natural process of aging. Cognitive impairment can be related to hallucinations, personality changes, depression symptoms, anxiety symptoms, loss of self and confusion. It is said to be due to the increase in the number of elderly people worldwide, but it is also reported that it is caused in young people and that cognitive impairment and dementia are caused by depression in young people.

[0015] As a result of extensive investigation, the present inventors have found that phosphoethanolamine itself is useful for preventing and alleviating psychological disorders.

[0016] In addition to the above, in the first place, generally speaking, since there are various marker substances, it is common technical knowledge in the field to which the present invention belongs that what is useful as a marker substance is not necessarily effective as a therapeutic agent. Therefore, the effect of the present invention is not predictable from the prior art. A method for determining other symptoms such as cognitive impairment, movement disorder, chronic pain, decreased motivation, and loss of appetite from a pre-disease state may also be provided. [Brief description of the drawings]

[0017] [Figure 1] Effect of intraperitoneal administration of PEA on behavioral changes induced by chronic social stress (1) [Diagram 2] Effect of intraperitoneal administration of PEA on behavioral changes induced by chronic social stress (2) [Diagram 3] Effect of intraperitoneal administration of PEA on behavioral changes induced by chronic social stress (3) [Figure 4]Effect of oral administration of PEA on behavioral changes induced by chronic social stress (1) [Diagram 5] Effect of oral administration of PEA on behavioral changes induced by chronic social stress (2) [Figure 6] Effect of oral administration of PEA on behavioral changes induced by chronic social stress (3) [Figure 7] Effect of intraperitoneal administration of PEA on changes in blood cells induced by chronic social stress (4) [Figure 8] Effect of intraperitoneal administration of PEA on changes in blood cells induced by chronic social stress (5) [Figure 9] Effect of intraperitoneal administration of PEA on changes in blood cells induced by chronic social stress (6) [Figure 10] Effect of intraperitoneal administration of PEA on changes in blood cells induced by chronic social stress (7) [Figure 11] Effect of oral administration of PEA on changes in blood cells induced by chronic social stress (4) [Figure 12] Effect of oral administration of PEA on changes in blood cells induced by chronic social stress (5) [Figure 13] Effect of oral administration of PEA on changes in blood cells induced by chronic social stress (6) [Figure 14] Effect of oral administration of PEA on changes in blood cells induced by chronic social stress (7) [Figure 15] Effect of PEA on fibrinogen / fibrin deposition following chronic social stress [Figure 16] Effect of PEA on bone marrow vascular permeability induced by chronic social stress [Figure 17] Results of social interaction tests conducted after chronic social defeat stress DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] Composition for preventing or alleviating psychological disorders The present invention provides an agent for preventing or alleviating psychological disorders, which comprises phosphoethanolamine (PEA) or a salt thereof as an active ingredient. Hereinafter, in this specification, an agent for preventing or alleviating psychological disorders, which comprises phosphoethanolamine (PEA) or a salt thereof as an active ingredient, may be simply referred to as the preventive or alleviating agent of the present invention.

[0019] Phosphoethanolamine, the active ingredient of the present invention, is a known compound having the following structure:

[0020] [ka]

[0021] In the present invention, phosphoethanolamine may be used in the form of a salt. In this embodiment, the salt refers to a salt that is pharma- ceutical or food acceptable. The salt of phosphoethanolamine also includes an acid addition salt and a base salt. Specific examples of acid addition salts include inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, perchlorate, and phosphate, organic acid salts such as oxalate, malonate, succinate, maleate, fumarate, lactate, malate, citrate, tartrate, benzoate, trifluoroacetate, acetate, methanesulfonate, p-toluenesulfonate, and trifluoromethanesulfonate, and acidic amino acid salts such as glutamate and aspartate. Specific examples of salts with bases include alkali metal or alkaline earth metal salts such as sodium salt, potassium salt, magnesium salt, zinc salt, or calcium salt, salts with organic bases such as pyridine salt and triethylamine salt, and salts with basic amino acids such as lysine and arginine.

[0022] The psychological disorder that the present invention targets refers to a state of having a precursor psychological disorder such as depression, anxiety, cognitive impairment, etc. The psychological disorder that the present invention targets also includes not only psychological disorders such as depression, anxiety, cognitive impairment, etc., but also states that are not diagnosed as psychological disorders but have psychological abnormalities. The psychological disorders and psychological stresses that the present invention includes include, for example, chronic stress, chronic fatigue caused by chronic stress, depression, perinatal depression, adjustment disorder, anxiety disorder, bipolar disorder, obsessive-compulsive disorder, etc., and typically include depression, etc. In the present invention, the state of psychological disorders in a pre-disease state that is not diagnosed as a disease includes, for example, depression, melancholy, loss of interest, loss of joy, impatience, fatigue, worthlessness, inappropriate guilt, loss of thinking and concentration, difficulty in making decisions, suicidal thoughts, loss of motivation, sleep disorder, loss of appetite, malaise, vague complaints, social defeat, loss of motivation, loss of motivation, loss of vitality, loss of self-confidence, loss of curiosity, loss of positive feeling due to failure to recover from depression, tendency to cry easily, etc., and refers to the simultaneous occurrence of one or more of these.The present invention is particularly effective against psychological disorders caused by chronic stress. In addition, in the present invention, "prevention or alleviation of psychological disorders" includes maintaining a psychological state without worsening it, specifically, for example, maintaining a positive mood, maintaining cognitive function (including a part of cognitive function (e.g., maintaining spatial awareness and the ability to remember and recall words, shapes, etc.)); suppressing, reducing, alleviating, etc., temporary deterioration of a psychological state, specifically, alleviating temporary anxiety, depressed mood, confusion, etc., and making a temporarily depressed mood positive, etc.

[0023] In the present invention, the phosphoethanolamine or a salt thereof, which is the active ingredient of the present invention, may be used as the preventive or mitigating agent of the present invention, or the phosphoethanolamine or a salt thereof may be used as a solid preparation, semi-solid preparation, or liquid preparation in which the phosphoethanolamine or a salt thereof is combined with various carriers that are pharma- ceutically acceptable or can be added to foods (e.g., isotonicity agents, chelating agents, stabilizers, pH regulators, preservatives, antioxidants, solubilizers, thickeners, excipients, binders, etc.). In this embodiment, the content of phosphoethanolamine or a salt thereof in the preventive or mitigating agent composition is not limited, but can be appropriately set within the range of, for example, 0.01% by mass or more, 0.1% by mass or more, 1% by mass or more, 5% by mass or more, 10% by mass or more, 20% by mass or more, 30% by mass or more, 40% by mass or more, 50% by mass or more, 60% by mass or more, 70% by mass or more, 80% by mass or more, 90% by mass or more, 95% by mass or more, 99% by mass or more, etc.

[0024] Examples of the isotonicity agent include sugars such as glucose, trehalose, lactose, fructose, mannitol, xylitol, sorbitol, etc., polyhydric alcohols such as glycerin, polyethylene glycol, propylene glycol, etc., inorganic salts such as sodium chloride, potassium chloride, calcium chloride, etc. These isotonicity agents can be used alone or in combination of two or more.

[0025] Examples of the chelating agent include edetate salts such as disodium edetate, calcium disodium edetate, trisodium edetate, tetrasodium edetate, calcium edetate, ethylenediaminetetraacetate, nitrilotriacetic acid or a salt thereof, sodium hexametaphosphate, citric acid, etc. These chelating agents may be used alone or in combination of two or more.

[0026] An example of the stabilizer is sodium hydrogen sulfite.

[0027] Examples of pH adjusters include acids such as hydrochloric acid, carbonic acid, acetic acid, citric acid, etc., and further include alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, etc., alkali metal carbonates or hydrogen carbonates such as sodium carbonate, alkali metal acetates such as sodium acetate, alkali metal citrates such as sodium citrate, bases such as trometamol, etc. These pH adjusters can be used alone or in combination of two or more.

[0028] Examples of preservatives include sorbic acid, potassium sorbate, paraoxybenzoic acid esters such as methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, and butyl paraoxybenzoate, chlorhexidine gluconate, quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride, and cetylpyridinium chloride, alkylpolyaminoethylglycine, chlorobutanol, polyquad, polyhexamethylene biguanide, and chlorhexidine, etc. These preservatives may be used alone or in combination of two or more.

[0029] Examples of antioxidants include sodium hydrogen sulfite, dry sodium sulfite, sodium pyrosulfite, concentrated mixed tocopherols, etc. These antioxidants may be used alone or in combination of two or more.

[0030] Examples of solubilizing agents include sodium benzoate, glycerin, D-sorbitol, glucose, propylene glycol, hydroxypropylmethylcellulose, polyvinylpyrrolidone, macrogol, D-mannitol, etc. These solubilizing agents can be used alone or in combination of two or more.

[0031] Examples of thickening agents include polyethylene glycol, methylcellulose, ethylcellulose, carmellose sodium, xanthan gum, sodium chondroitin sulfate, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, etc. These thickening agents can be used alone or in combination of two or more.

[0032] Examples of the excipient include lactose, corn starch, L-cysteine, trehalose, maltitol, sorbitol, etc. These excipients may be used alone or in combination of two or more.

[0033] Examples of binders include crystalline cellulose, starch, sucrose, hydroxypropyl cellulose, gelatin, powdered gum arabic, polyvinylpyrrolidone, pullulan, dextrin, cyclodextrin, methyl cellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl alcohol, polyethylene glycol, various derivatives, etc. These binders may be used alone or in combination of two or more.

[0034] In addition, the composition may further contain a substance known to have a function of preventing or alleviating psychological disorders, in addition to phosphoethanolamine or a salt thereof. Examples of substances known to have a function of preventing or alleviating psychological disorders include GABA, 3-hydroxybutyric acid, 2-aminobutyric acid, L-theanine, flavonoid glycosides, lactic acid bacteria, etc. These substances can be used alone or in combination of two or more.

[0035] When a subject (preferably a mammal such as a human) ingests the prophylactic or alleviating agent of the present invention, it brings about an effect of preventing or alleviating psychological disorders. The amount of intake of the prophylactic or alleviating agent of the present invention is not limited, but the daily intake of the active ingredient phosphoethanolamine is preferably in the range of, for example, about 10 to 5000 mg, more preferably 100 to 1000 mg.

[0036] The preventive or mitigating agent of the present invention includes foods and beverages, pharmaceuticals, etc. In the present invention, the foods and beverages also include health functional foods (nutritional functional foods, foods for specified health uses, foods with functional claims), etc. All foods in the usual sense are included, and may be mixed with terms such as the above-mentioned foods that are known in the technical field.

[0037] Examples of foods and beverages include coffee, tea, fruit juice, carbonated water, beverages derived from plants, soft drinks, alcohol, various soups, meat, fish, sausages, pizza, bread, noodles, confectionery, gums, gummy candies, chocolates, candies, foods using agar or gelatin such as jelly, dairy products such as ice cream and yogurt, etc. In an embodiment of a food and beverage, the preventive or palliative agent of the present invention also includes supplements (tablet type, powder type, etc.), etc. Also included are foods used as animal feed.

[0038] Examples of animals to which the present invention can be applied include mammals such as humans, monkeys, mice, rats, guinea pigs, dogs, cats, cows, horses, and pigs.

[0039] Specific embodiments of the present invention will be described in detail below using examples and comparative examples, but the present invention is not limited to the following examples. EXAMPLES

[0040] [method] 1. Mouse All animal care and experimental procedures conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee of the Kobe University Graduate School of Medicine. Male C57BL / 6N and male ICR retired mice, retired from breeding, were purchased from Japan SLC (Hamamatsu, Japan). Mice were kept in a specific pathogen-free, temperature- and humidity-controlled animal facility under a 12-h light / dark cycle (lights on between 6:00 and 18:00) with free access to food and water. C57BL / 6N mice purchased from Japan SLC were kept in the animal experimental facility of the Kobe University Graduate School of Medicine for at least 1 week before use in experiments. To reduce animal suffering, the health of all mice was continuously monitored throughout the experiment by well-trained experimenters following approved protocols. Mice were euthanized by deep anesthesia with isoflurane or lethal injection of sodium pentobarbital before tissue collection or at the end of the experiment, or at a humane endpoint.

[0041] 2. Administration of phosphoethanolamine and a peroxisome proliferator-activated receptor δ (PPAR δ) antagonist (GSK3787) Phosphoethanolamine (PEA) (Sigma-Aldrich, St. Louis, MO, USA) was administered intraperitoneally or orally. For the intraperitoneal administration group, PEA was dissolved in saline (Otsuka Normal Saline, Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan) at 10 mg / kg and administered intraperitoneally at 10 mL / kg body weight. For the experiment in which a PPARδ antagonist was administered, the PPARδ antagonist (GSK3787, Cayman Chemical, 15219) and PEA were dissolved in 5% dimethyl sulfoxide / saline and administered intraperitoneally at 20 mg / kg for GSK3787 and 10 mg / kg for PEA at 10 mL / kg. For oral administration, phosphoethanolamine was dissolved in 0.5 w / v% methylcellulose 400 solution (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) at 10 mg / kg and administered via oral gavage at a volume of 10 mL per kg of mouse body weight. Administration was performed once a day, approximately 30 minutes before social defeat stress during the stress period and after the behavioral test during the behavioral test period. Mice in the control group (vehicle group) were administered saline (intraperitoneally) or 0.5 w / v% methylcellulose 400 solution (orally) at the same time as the PEA-administered group. Administration was also performed 30 minutes before blood and tissue sampling.

[0042] 3. Chronic social defeat stress Mice were subjected to chronic social defeat stress according to the following paper (Ishikawa et al., Br J Pharmacol, 2021). The attacking ICR mice were selected based on their 180-second attack latency and number of attacks against male C57BL / 6N mice. Male C57BL / 6N mice, which served as experimental controls, and control mice were housed in groups of three per cage and subjected to chronic social defeat stress at the age of 9 weeks. The attacking ICR mice were introduced into the cages of C57BL / 6N mice for 2 hours per day for six consecutive days and subjected to social defeat. If the ICR mice did not initiate an attack within 10 minutes, they were replaced with new ICR mice. Different ICR mice were used every day. It was observed that the C57BL / 6N mice showed a submissive posture in each session. After 2 hours of social defeat, the ICR mice were removed from the cage and left in their home cage until social defeat the next day. The control group cages were left undisturbed for the six-day experimental period without any ICR mice being introduced. The following behavioral tests were performed on the mice that had been subjected to chronic social defeat stress by the above method and the control group mice.

[0043] 4. Behavioral Testing Depressive-like behavior was assessed using the social interaction test and tail suspension test, and cognitive impairment was assessed using the novel object recognition test. All behavioral tests were performed during the light phase after 1 h of habituation to a soundproof room prior to each test.

[0044] Social interaction test: The social interaction test was performed according to the following paper (Ishikawa et al., Br J Pharmacol, 2021). A wire mesh cage (10 cm wide x 6 cm deep; O'Hara, Tokyo, Japan) was placed at one end of an open-field chamber (42 cm wide x 42 cm deep x 40 cm high) illuminated with 10 Lux red light. C57BL / 6N mice were introduced here and allowed to habituate to the open-field chamber without social stimuli for 150 seconds. After that, the C57BL / 6N mice were introduced into the open-field chamber containing a wire mesh cage containing a novel ICR mouse for 150 seconds. The mouse behavior was video-recorded, and the trajectory of the mouse's walking was automatically detected using a SMART video tracking system (Harvard Apparatus; Holliston, MA, USA). The percentage of time that C57BL / 6N mice spent in the interaction zone (8 cm perimeter of the wire mesh cage) and the social avoidance zone (two 9 cm x 9 cm squares in the corners of the field on opposite sides of the wire mesh cage) was determined and used as behavioral indices of social interaction and social avoidance, respectively.

[0045] Novel object recognition test: The novel object recognition test was performed according to the following paper with some modifications (Leger et al., Nat Protoc, 2013). C57BL / 6N mice were placed in an open-field chamber (42 cm wide x 42 cm deep x 40 cm high) illuminated with 15 Lux white light and allowed to freely explore two identical objects. The mouse was allowed to explore the two objects when the total exploration time for the two objects reached 20 s or 10 min had elapsed. After a 4-hour interval, one of the objects was replaced with a novel object, and the mouse was allowed to explore the two objects again. As in the first session, the test was allowed to end when the total exploration time for the two objects reached 20 s or 10 min had elapsed. The novel object selection rate was calculated by dividing the time spent exploring the novel object by the sum of the time spent exploring the two objects and multiplying by 100.

[0046] Tail suspension test: The tail suspension test was performed according to the following paper with some modifications (Can et al., J Vis Exp, 2012). The tails of C57BL / 6N mice were hung with adhesive tape from an iron bar placed 50 cm above the floor, and the behavior of the mice was recorded by a video camera for 6 min. The tails of the mice were passed through a plastic tube to prevent the mice from climbing onto their own tails. Mice that fell during the test were excluded from the analysis. The time spent immobile during the 6 min test period was scored blinded to the experimental conditions.

[0047] 5. Isolation of Cells from Blood, Bone Marrow, Spleen, and Brain Blood, bone marrow, and spleen cells were isolated according to the following publications with minor modifications (Engler et al., J Neuroimmunol, 2004; Katayama et al., Cell, 2006). Control or chronic social stressed C57BL / 6N mice were deeply anesthetized by inhalation of isoflurane or injection of sodium pentobarbital. Peripheral blood was collected from the heart using an EDTA-coated syringe. White blood cell and platelet counts were measured using an automated hemocytometer (Nihon Kohden, Tokyo, Japan). Bone marrow was flushed from femurs with 850 μL ice-cold RPMI (FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan), and the total number of cells was counted using a hemocytometer (MEK-6558, Wakenbtech, Kyoto, Japan). Spleens were collected in ice-cold RPMI and gently squeezed through a 70 μm cell strainer to obtain a single cell suspension. Erythrocytes were lysed with erythrocyte lysis buffer (150-mM NH4Cl, 10-mM NaHCO3, and 1-mM EDTA), and the total number of leukocytes was measured using a hemocytometer. The brains were collected after perfusion of mice with ice-cold PBS, and gently squeezed with a 70-μm cell strainer to obtain a cell suspension. The brains were washed with RPMI, and centrifuged at 800 g for 25 min at 4°C using a density gradient solution of Percoll (GE HealthCare, Chicago, IL, USA) to obtain a cell fraction containing neutrophils. The cell fraction was further centrifuged at 600 g for 6 min at 4°C, and the supernatant was removed. The cell pellet was suspended in PBS containing 0.5% BSA and 0.5 M EDTA, and centrifuged at 400 g for 6 min at 4°C, and the supernatant was removed. The cell pellet was further resuspended in PBS containing 0.5% BSA and 0.5 M EDTA to obtain a single cell suspension containing neutrophils. Tissues and blood were collected between 8 am and noon.

[0048] 6. Flow Cytometry Flow cytometry was performed according to the following publications (Kawano et al., Blood, 2017; Ishikawa et al., Br J Pharmacol, 2021). To block nonspecific binding of antibodies to Fc receptors, blood cells, bone marrow cells, spleen cells, and brain cells were incubated with anti-CD16 / CD32 antibody (clone 93, BioLegend, SanDiego, CA, USA) on ice for 10 minutes, and then incubated with fluorescently labeled antibodies shown in Table 1 below on ice for 15 minutes.

[0049] [Table 1] Nonspecific binding was assessed using isotype control antibodies or appropriate control antibodies. Fluorescent signals were measured using a CytoFLEX S (Beckman Coulter, Brea, CA, USA). Data analysis was performed using FlowJo software (FlowJo LLC, BD Biosciences; RRID:SCR_008520).

[0050] 7. Immunohistochemical staining Approximately 15 hours after chronic social defeat stress, mice were deeply anesthetized with isoflurane and perfused with 60 mL of cold PBS, followed by 30 mL of cold 4% paraformaldehyde (PFA)·0.1 M phosphate buffer. The brains were then harvested and fixed overnight at 4°C in 4% PFA·phosphate buffer, then cryoprotected by immersion in 30% sucrose·PBS solution for 48 hours. The brains were then embedded in OCT compound (Sakura Finetek) and cut into 30 μm-thick coronal sections using a cryostat (Leica). The brain sections were washed three times for 10 min with PBS and blocked with blocking buffer (5% BSA / 0.3% Triron X-100 / PBS solution) for 1 h at room temperature. Brain sections were then incubated overnight at 4°C with primary antibodies (rabbit anti-fibrinogen, 1:1000 dilution, DAKO, A0080; rat anti-CD31, 1:150 dilution, BD Pharmingen, 550274) dissolved in 1% BSA / 0.1% Triron X-100 / PBS solution. After washing three times for 5 min with 0.1% Triron X-100 / PBS solution, brain sections were incubated for 1 h at room temperature with secondary antibodies (Alexa Fluor 488-conjugated donkey anti-rabbit IgG, 1:1000 dilution, Thermo Fisher Scientific, A21206; Alexa Fluor 555-conjugated donkey anti-rat IgG, 1:1000 dilution, Abcam, ab150154) dissolved in 0.1% Triron X-100 / PBS solution. Brain sections were washed again three times with PBS and incubated with Hoechst 33342 (1:5000 dilution, Thermo Fisher Scientific, H3570) for 15 min at room temperature to visualize cell nuclei. After washing the brain sections with PBS, they were attached to APS-coated slides and mounted under coverslips with ProLong Gold Antifade Regent (Thermo Fisher Scientific). Fluorescent images were taken with a BZ-X710 (Keyence) and LSM700 confocal laser microscope (Carl Zeiss) using a 10x or 63x objective. Six images were taken from each mouse in the prefrontal cortex, nucleus accumbens, hippocampus, and somatosensory cortex.The area of ​​fibrinogen / fibrin deposition was quantified using Image J software.

[0051] 8. Bone Marrow Vascular Permeability Assessment Bone marrow vascular permeability was assessed by Evans Blue dye assay according to the following papers with some modifications (Bowers et al., Nat Med, 2018; Matsumoto et al., Exp Hematol, 2021). Mice were anesthetized with isoflurane, and approximately 14 hours after chronic social defeat stress, 2% Evans Blue (Sigma-Aldrich) dissolved in saline was administered into the orbital venous plexus at a volume of 10 mL / kg. Twenty minutes after administration, one femur was removed and the femur was washed with 500 μL of cold PBS using a 1 mL syringe equipped with a 21G needle. The suspension was centrifuged (1500 rpm, 4 °C, 5 min), and the supernatant was collected. The amount of Evans Blue in the 96-well plate was measured by absorbance at 620 nm using an absorbance microplate reader (iMARKTM, Bio-Rad Laboratories).

[0052] 9.Statistical analysis Data are presented as mean ± SEM. Two-way ANOVA was used to test for statistical significance. If at least one main effect of a factor or an interaction between two factors was statistically significant, pairwise comparisons were performed with Bonferroni's multiple comparison test. P < 0.05 was considered significant. Statistical analyses were performed using GraphPad Prism 9 software (GraphPad Software, La Jolla, CA, USA). [result] The results of the social interaction test are shown in Figures 1 and 4. The vertical axis indicates the percentage of time spent in the aversion zone during the 150-second test. In the vehicle group, mice exposed to chronic social defeat stress showed increased social avoidance behavior compared to mice not exposed to chronic social defeat stress. In contrast, in the PEA-administered group, mice exposed to chronic social defeat stress showed suppressed induction of social avoidance behavior compared to mice not exposed to chronic social defeat stress.

[0053] The results of the novel object recognition test are shown in Figures 2 and 5. The vertical axis indicates the novel object selection rate. In the vehicle group, the mice exposed to chronic social defeat stress had a decreased novel object selection rate compared to the mice not exposed to chronic social defeat stress. In contrast, in the PEA-administered group, the mice exposed to chronic social defeat stress did not show a decrease in the novel object selection rate compared to the mice not exposed to chronic social defeat stress.

[0054] The results of the tail suspension test are shown in Figures 3 and 6. The vertical axis indicates immobility time. In the vehicle group, mice exposed to chronic social defeat stress showed an increase in immobility time compared to mice not exposed to chronic social defeat stress. In contrast, in the PEA-administered group, the increase in immobility time was suppressed in mice exposed to chronic social defeat stress compared to mice not exposed to chronic social defeat stress.

[0055] The effect of intraperitoneal administration of PEA on blood cell changes caused by chronic social stress is shown in Figures 7 to 10. The number of neutrophils in the bone marrow after chronic social defeat stress increased in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of monocytes in the bone marrow after chronic social defeat stress increased in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of neutrophils in the spleen after chronic social defeat stress increased in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of monocytes in the spleen after chronic social defeat stress increased in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of spleen cells after chronic social defeat stress increased in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of neutrophils in the circulating blood after chronic social defeat stress increased in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of monocytes in the circulating blood after chronic social defeat stress was decreased in the PEA-treated group compared to the vehicle-treated group. The number of neutrophils in the brain after chronic social defeat stress was increased by chronic social defeat stress in the vehicle-treated group, but this increase was suppressed in the PEA-treated group.

[0056] The effect of oral administration of PEA on blood cell changes caused by chronic social stress is shown in Figures 11 to 14. The number of neutrophils in the bone marrow after chronic social defeat stress was increased by chronic social defeat stress in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of neutrophils in the spleen after chronic social defeat stress was increased by chronic social defeat stress in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of monocytes in the spleen after chronic social defeat stress was increased by chronic social defeat stress in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of neutrophils in the circulating blood after chronic social defeat stress was increased by chronic social defeat stress in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of leukocytes in the circulating blood after chronic social defeat stress was increased by chronic social defeat stress in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of platelets in the circulating blood after chronic social defeat stress was increased by chronic social defeat stress in the vehicle-treated group, but the increase was suppressed in the PEA-treated group. The number of brain neutrophils after chronic social defeat stress increased in the vehicle-treated group, but the increase was suppressed in the PEA-treated group.

[0057] The effect of PEA on fibrinogen / fibrin deposition by chronic social stress is shown in Figure 15. Representative immunofluorescence staining images of fibrinogen / fibrin deposition in brain sections after chronic social defeat stress are shown in Figure 15(A), and a coronal section atlas depicting the deposition is shown in Figure 15(B). In the vehicle-treated group, chronic social defeat stress induced fibrinogen / fibrin deposition throughout the brain, but PEA administration attenuated the deposition. Figure 15(C) shows representative immunofluorescence staining images of fibrinogen / fibrin deposits (green) in the prefrontal cortex, nucleus accumbens, hippocampus, and somatosensory cortex. Blood vessels and nuclei are labeled with anti-CD31 antibody (red) and Hoechst (blue), respectively. Fibrinogen / fibrin deposits due to chronic social defeat stress were frequently observed in the dorsal lateral part of the cerebral cortex, such as the somatosensory cortex, and were also observed in brain regions involved in stress, such as the prefrontal cortex, nucleus accumbens, and hippocampus. Co-staining with the endothelial cell marker CD31 revealed that most fibrinogen / fibrin deposits were localized in the vascular membrane and lumen, with some deposits also observed in the brain parenchyma, suggesting cerebrovascular disorders and blood-brain barrier disorders.

[0058] Quantification of fibrinogen / fibrin deposition in each brain region after chronic social defeat stress and PEA administration is shown in Figure 15(D)-(G). In the prefrontal cortex (Figure 15(D)), nucleus accumbens (Figure 15(E)), hippocampus (Figure 15(F)), and somatosensory cortex (Figure 15(G)), chronic social defeat stress increased the area of ​​fibrinogen / fibrin deposition in the vehicle-treated group, but decreased the area of ​​deposition in the PEA-treated group.

[0059] The effect of PEA on bone marrow vascular permeability increase due to chronic social stress is shown in Figure 16. Specifically, Figure 16 shows the amount of Evans blue leaking into the bone marrow after chronic social defeat stress. In the vehicle-treated group, chronic social defeat stress increased the amount of Evans blue leaking into the bone marrow, suggesting an increase in vascular permeability, but in the PEA-treated group, leakage was attenuated.

[0060] The results of the social interaction test conducted after chronic social defeat stress are shown in Figure 17. The vertical axis indicates the percentage of time spent in the aversion behavior zone during the 150-second test. The increase in social avoidance behavior caused by chronic social defeat stress was attenuated by administration of PEA, but this inhibitory effect disappeared by simultaneous administration of a PPARδ antagonist. The results of Figure 17 suggest that PPARδ is involved in the prevention or alleviation of psychological disorders by PEA.

[0061] As shown in the above examples, phosphoethanolamine is very useful for preventing or alleviating psychological disorders that may lead to depression or cognitive decline. Also, as shown in the above examples, phosphoethanolamine inhibits neutrophil mobilization, thereby alleviating psychological conditions. It is a new finding that has never been reported before that phosphoethanolamine inhibits neutrophil mobilization, and that inhibition of neutrophil mobilization alleviates psychological disorders. Therefore, the present invention can alleviate psychological conditions such as depression through a mechanism different from that known as a drug for treating depression, and is also very useful from this point of view.

Claims

1. An agent for preventing or alleviating psychological disorders, comprising phosphoethanolamine or a salt thereof as an active ingredient.

2. The method according to claim 1 , wherein the psychological disorder is a condition caused by psychological stress.

3. The method according to claim 1 , wherein the psychological disorder is at least one selected from the group consisting of cognitive disorder, social activity disorder, and mental disorder.

4. The preventive or alleviating agent according to claim 1 , which is for oral intake or injection administration.

5. The preventive or alleviating agent according to claim 1 , which is a food, beverage or medicine.

Citation Information

Patent Citations

  • Composition for preventing or ameliorating dementia or depression

    JP2022058747A